Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
Go back to Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
April 4, 2016 6:21 AM EDT
Leerink Partners analyst Geoffrey Porges reiterated an Outperform rating and boosted his price target on Regeneron Pharma (NASDAQ: REGN) to $523.00 (from $505.00) after dupilumab was substantially de-risked for the atopic dermatitis (AD) indication, and, they believe, for other indications as well (for safety).
"Our... More
April 1, 2016 12:12 PM EDT
Regeneron (NASDAQ: REGN) shares keep ramping higher. The stock is now up 11.3 percent and has crossed above the $400 levle.
Earlier, Regeneron and Sanofi announced that two placebo-controlled Phase 3 studies evaluating investigational dupilumab in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD) met their primary endpoints.
...
More
April 1, 2016 11:52 AM EDT
Baird reiterated an Outperform rating and $526.00 price target on Regeneron Pharma (NASDAQ: REGN) following the company's release of Dupilumab's phase III atopic dermatitis phase III data. The two Phase III studies, SOLO 1 and SOLO 2, enrolled 1,379 adult patients with moderate-to-severe AD. The FDA's... More
April 1, 2016 10:55 AM EDT
Roth Capital analyst Joseph Pantginis trimmed his price target on Regeneron Pharma (NASDAQ: REGN) to $520.00 (from $555.00) but maintained a Buy rating after Dupilumab (Breakthrough Designation) delivered two positive Phase III studies in moderate-to-severe atopic dermatitis.
"The BLA filing is expected in 3Q16 and... More
